Bespak and Aesica have launched a new single source supply chain service for drug delivery products incorporating formulation development, device design and development, drug and device manufacture, fill/finish and secondary packaging.The new business model aims to streamline and reduce cost and complexity of development.
 
Following Consort Medical’s acquisition of Aesica, the company has combined and integrated Aesica’s drug formulation, manufacturing and packaging capabilities with Bespak’s drug delivery device, design, development and manufacturing services for pharmaceutical customers. The Group now provides inhalation, nasal, ocular, Buccal, and transdermal drug delivery device concept generation, design, development, and manufacture at pilot through to high volume commercial scale, as well as API and formulation development and manufacture and finished dose fill/finish.
 
Bespak and Aesica have synergies across quality control, regulatory compliance and manufacturing. This includes QP release and ISO certified Quality Management Systems, cGMP compliance and operating to FDA and MHRA standards of approval.
 
Aesica facilities can handle up to schedule 2 controlled substances, together with a high containment suite capable of manufacturing products in the SafeBridge category 3 potency level. Both brands provide pilot up to volume manufacturing – operating at scales from low volume pilot manufacture to very high volume automated production operations and from grams to full scale manufacture of drugs.